MorphImmune
Biotechnology ResearchIndiana, United States0-1 Employees
MorphImmune is a preclinical biotechnology company focused on developing targeted oncology therapeutics. The company's proprietary Targeted Effector platform selectively delivers payloads to diseased cells. The targeted approach reduces toxicity and increases efficacy of known effector molecules, ultimately improving outcomes for patients.